With nearly 20 years of experience in software and more than a decade guiding Innerspace’s technical direction, Andreas Berger focuses on bridging the gap between complex demands of the pharmaceutical industry and scalable technological solutions.

Innerspace originally started with VR training to support human behavior, workforce excellence, and GMP-compliant performance in aseptic pharmaceutical manufacturing.

From the beginning, the company’s mission was to help pharmaceutical manufacturers improve quality risk management (QRM) by strengthening how people understand and execute critical processes.

Through close collaboration with leading pharmaceutical companies worldwide, a broader perspective emerged: training was only one part of a larger system. Meaningful impact requires a holistic view of the interaction between processes, equipment, and people.

By listening closely to customer challenges, recurring patterns became visible to the Innerspace team. While some risks in the aseptic production process were obvious, others were subtle, context-dependent, and deeply embedded in process execution.

Andreas Berger refers to these as ‘conscious risks’ that can be managed through training, but also as risks the pharma industry has simply come to accept and live with – yet a significant portion of risks often stems from completely unknown or invisible areas of the process.

Translating these market insights into a reliable technical framework became the foundation for Frame-by-Frame®, Innerspace’s proprietary technology.

Developed and continuously refined by a dedicated team of technical experts, Frame-by-Frame® translates complex aseptic manufacturing operations into a structured digital process model.

This digital process model serves as the foundation for analyzing process execution, identifying risk-relevant patterns, and comparing process variants, while ultimately supporting implementation and connecting process knowledge with targeted training.

Through Frame-by-Frame®, Andreas and the Innerspace team scales this expertise across the entire product lifecycle: from digitalizing complete production lines – whether they are currently running, being expanded, aligned across multiple sites, or still in the conception and planning phase – to simulate and optimize critical process steps as delivering targeted training solutions.

Today, while the global business landscape rushes to talk about AI, Andreas ensures that the Innerspace engineering and data teams stay focused on the true foundational pillars: clean data architecture, solid data mining, statistical analysis and targeted application of machine learning.

For Andreas, AI is not a magical standalone solution but a powerful tool that delivers maximum value to the pharmaceutical industry especially when it comes to aseptic production only when built upon a standardized, high-quality data foundation.

As AI plays an increasingly important role in the pharmaceutical industry, Andreas Berger and the Innerspace team of experts believe that the true differentiator will not be the technology itself but the deliberate and focused use of AI based on structured data.

Ultimately, the core mission of Andreas Berger as an Innerspace co-founder remains unchanged: listening closely to the needs of the industry and guiding the team to capture, digitalize, and optimize the intersection of process, equipment, and people – all grounded in a consistent, reusable data source.